Motus GI Holdings, a medical technology company, reported its Q1 2024 financial results and corporate updates. The U.S. launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system doubled the number of active customers, with 100% adopting the system independently. The company appointed an investment bank to explore strategic alternatives to boost commercialization and stockholder value. Revenues for Q1 2024 increased to $64,000 from $56,000 in Q1 2023, primarily from disposable sleeve reorders. Despite this, the net loss deepened to $7.6 million from $4.4 million year-over-year. Cash and equivalents stood at $4.9 million as of March 31, 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.